Companies Investors People

Drop to look up

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

Get in Touch

Contact
Request a Demo
Request Data Updates
Add a Company

Research

Companies
Investors
People

aVenture

Download App
Pricing
For Startups
Alternatives

For iPhone and iPad

Resources

Documentation
Use Cases
CLI
MCP
Sitemap

aVenture is an AI-native agentic deep research tool for researching and finding companies and people, and is a high-quality alternative to AlphaSense, CB Insights, Crunchbase, Dealroom, Harmonic, Owler, Perplexity Finance, PitchBook, Preqin, PrivCo, Synaptic, and Tracxn.

Member

Backed by

Ask AI about aVenture

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Terms of service

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Identifai Genetics/

Library

Identifai Genetics

Identifai Genetics Website, Blog & Press Pages - aVenture Research

Library

identifai-genetics.comCrawled Nov 9, 2026

Topics

Publication type

Search the library

Content origin

Row density

Product

3 pages

Clinical Trials/clinical-trials
Identifai Genetics partners with clinical sites in the United States to evaluate next-generation prenatal genetic screening.
Products/products
On the Horizon, Windrose will transform prenatal screening with a single maternal blood draw, predicting fetal genetic variants at single-letter resolution from week 9 of pregnancy to provide clinicians and families with earlier, clearer insights.
Technology White Paper/technology-white-paper
irth defects are innate developmental errors, encompassing structural or functional irregularities that impact physical, mental, and social wellbeing.

Blog

6 pages

Bayesian-based noninvasive prenatal diagnosis of single-gene disorders/bayesian-based-noninvasive-prenatal-diagnosis-of-single-gene-disorders
Noninvasive prenatal diagnosis (NIPD) detects inherited diseases early in pregnancy using cell-free DNA (cfDNA) and fetal cfDNA (cffDNA) from maternal blood, posing minimal risk to mother and fetus.
Decoding DNA To Birth Defects In Unborn Babies/decoding-dna-to-birth-defects-in-unborn-babies
Israeli startup Identifai Genetics says it can determine whether a baby will be born with any kind of genetic disorder, using a simple and inexpensive blood test to analyze traces of the fetus’ DNA that is found in the mother’s blood.
Genome-wide noninvasive prenatal diagnosis of monogenic disorders: Current and future trends/genome-wide-noninvasive-prenatal-diagnosis-of-monogenic-disorders-current-and-future-trends
Noninvasive prenatal diagnosis (NIPD) offers a risk-free alternative to invasive prenatal testing, such as amniocentesis.
Improved noninvasive fetal variant calling using standardized benchmarking approaches/improved-noninvasive-fetal-variant-calling-using-standardized-benchmarking-approaches
The technology of noninvasive prenatal testing (NIPT) enables risk-free detection of genetic conditions in the fetus, by analysis of cell-free DNA (cfDNA) in maternal blood.

Press

4 pages

ASX Announcements/investor-centre/asx-announcements
Granted Patent: Gene Disorders identification in Maternal…/granted-patent-gene-disorders-identification-in-maternal
Identifai-Genetics wins IIA approval for a NIS 9M R&D Plan/identifai-genetics-wins-iia-approval-for-a-nis-9m-rd-plan
Identifai-Genetics received approval from the Israel Innovation Authority for a NIS 9 million R&D plan.
News/news

Careers & Hiring

1 page

Careers/careers
Identifai Genetics seeks employees passionate about innovation, scientific excellence, and genomic technology.

Team

6 pages

Gilad Magnazi/team/gilad-magnazi
Kobi Caspi/team/kobi-caspi
Lucy Robb Vujcic/team/lucy-robb-vujcic
Nilesh Dharajia/team/nilesh-dharajia

About

2 pages

About us/about-us
Clinically relevant and actionable screened
Corporate Governance/corporate-governance

Contact

1 page

Contact/contact
Identifai Genetics 1/295 Rokeby Rd, Subiaco WA 6008

Homepage

1 page

Homepage/
Identifai was established to enable comprehensive analysis of the fetal genome, providing a complete view of the fetus’s genetic health.

Privacy

1 page

Privacy Policy/privacy-policy
Identifai Genetics Limited handles personal information in line with Australia’s Privacy Act 1988.